文献速递艾滋病与性传播感染

ABX464在健康未感染HIV受试者中的药代动力学与耐受性

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

ABX464耐受良好,约2小时达峰,快速大量代谢为ABX464-NGlc,后者暴露量约为母药的160倍且半衰期长达90至110小时。

要点

  • ABX464单次口服50至200mg在健康未感染HIV男性中耐受良好。
  • 母药约2小时达峰,代谢物ABX464-NGlc约4小时达峰。
  • ABX464-NGlc暴露量约为母药的160倍,半衰期为90至110小时。

核心结论

  • ABX464在健康未感染HIV受试者中耐受良好,并快速大量代谢为ABX464-NGlc。

主要发现

  • 最常见治疗相关不良事件为头痛、恶心和呕吐,未被视为治疗限制性效应。
  • 所有剂量组ABX464的Cmax约在给药后2小时出现。
  • ABX464-NGlc的Cmax约在给药后4小时出现,约为母药的160倍,t1/2为90至110小时。
  • 代谢物与母药比值在整个剂量范围内一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An anti-HIV compound (ABX464) has been developed with a novel mechanism of activity in that it blocks viral gene expression in cells that are already infected. OBJECTIVES: A first-in-man study was conducted to determine the pharmacokinetic and safety profiles of ABX464. This was carried out as an open label, parallel group, single ascending dose, exploratory study. METHODS: Twenty-four male subjects in good health without HIV infection, aged from 18 to 55 years old, with BMIs of 18-27 kg/m 2 were included. A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days. Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464- N -glucuronide (ABX464-NGlc). The study was registered at https://www.clinicaltrials (trial number NCT02792686). RESULTS: ABX464 was well tolerated; the most frequent related treatment-emergent adverse events were headaches, nausea and vomiting; they were not considered as treatment-limiting effects. ABX464's C max was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGlc. The C max of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t 1/2 (90-110 h). The ratio of metabolite to parent drug was consistent across the complete dose range. CONCLUSIONS: These studies confirmed that ABX464 is well tolerated and rapidly and substantially metabolized into ABX464-NGlc in human subjects.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Scherrer D, Rouzier R, Noel Barrett P, et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects. J Antimicrob Chemother. 2017. PMID: 27999038. doi:10.1093/jac/dkw458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。